Nature Communications (Jul 2020)

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

  • David Simon,
  • Koray Tascilar,
  • Gerhard Krönke,
  • Arnd Kleyer,
  • Mario M. Zaiss,
  • Franz Heppt,
  • Christine Meder,
  • Raja Atreya,
  • Entcho Klenske,
  • Peter Dietrich,
  • Abdullah Abdullah,
  • Thorsten Kliem,
  • Giulia Corte,
  • Harriet Morf,
  • Moritz Leppkes,
  • Andreas E. Kremer,
  • Andreas Ramming,
  • Milena Pachowsky,
  • Florian Schuch,
  • Monika Ronneberger,
  • Stefan Kleinert,
  • Clara Maier,
  • Axel J. Hueber,
  • Karin Manger,
  • Bernhard Manger,
  • Carola Berking,
  • Matthias Tenbusch,
  • Klaus Überla,
  • Michael Sticherling,
  • Markus F. Neurath,
  • Georg Schett

DOI
https://doi.org/10.1038/s41467-020-17703-6
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 7

Abstract

Read online

Cytokine storm seems to be a common feature of severe COVID-19 pathology. Here, the authors show a reduced rate of SARS-CoV2 positivity in a large population of patients with immune-mediated inflammatory diseases if they are already being treated with cytokine or JAK inhibitors, indicating these treatments are safe to continue and are possibly protective against COVID19.